País: Malta
Idioma: inglés
Fuente: Medicines Authority
FLUCLOXACILLIN
Panpharma Z.I. DU CLAIRAY, 35133 LUITRE, France
J01CF05
FLUCLOXACILLIN 500 mg
POWDER FOR SOLUTION FOR INFUSION OR INJECTION
FLUCLOXACILLIN 500 mg
POM
ANTIBACTERIALS FOR SYSTEMIC USE
Authorised
2018-08-24
PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE PATIENT FLUCLOXACILLIN PANPHARMA 500 MG, POWDER FOR SOLUTION FOR INJECTION/INFUSION. Flucloxacillin sodium monohydrate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. The full name of this product is Flucloxacillin Panpharma 500 mg, powder for solution for injection/infusion, but within the leaflet it will be referred to as Flucloxacillin Panpharma. WHAT IS IN THIS LEAFLET 1. What FLUCLOXACILLIN PANPHARMA is and what it is used for 2. What you need to know before you are given FLUCLOXACILLIN PANPHARMA 3. How FLUCLOXACILLIN PANPHARMA is given 4. Possible side effects 5. How to store FLUCLOXACILLIN PANPHARMA 6. Contents of the pack and other information 1. WHAT FLUCLOXACILLIN PANPHARMA IS AND WHAT IT IS USED FOR Flucloxacillin Panpharma is an antibiotic belonging to a class of antibiotics called beta- lactamase resistant penicillins. The active substance is flucloxacillin. Flucloxacillin works by killing bacteria that cause infection. It only works with specific strains of bacteria. Fluclocaxillin Panpharma is used for the treatment of infections such as: • Skin and soft tissue infections, like abscesses, cellulitis (inflammation of tissue below the skin), infected burns, pustular dermatitis (impetigo) • Upper respiratory tract infections, like sore throat (pharyngitis, tonsillitis), inflammation of the sinuses (sinusitis) • Lower respiratory tract infections, like pneumonia, lung abscess, bronchopneumonia • Bone and joint infections, like bone and bone mar Leer el documento completo
Page 1 of 12 SUMMARY OF PRODUCT CHARACTERISTICS Page 2 of 12 1. NAME OF THE MEDICINAL PRODUCT Flucloxacillin Panpharma 500 mg, powder for solution for injection/infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 500 mg of flucloxacillin (equivalent to 544 mg of flucloxacillin sodium monohydrate). Excipient with known effect: sodium 1.10 mmol/vial. This medicine contains approximately 25.5 mg sodium per vial, equivalent to 1.275 % of the WHO recommended maximum daily intake of 2 g sodium for an adult. 3. PHARMACEUTICAL FORM Powder for solution for injection/infusion. Flucloxacillin sodium monohydrate is supplied as a white or almost white powder. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Flucloxacillin Panpharma is indicated for the treatment of the following infections due to beta- lactamase-producing staphylococci and other sensitive Gram-positive organisms such as streptococci (see section 4.2 and 5.1: • Skin and soft tissue infections like abscesses, cellulitis, infected burns, impetigo • Upper respiratory tract infections, like pharyngitis, tonsillitis, sinusitis • Lower respiratory tract infections, like pneumonia, bronchopneumonia, pulmonary abscess • Bone and joint infections like osteomyelitis and arthritis • Endocarditis • Prophylaxis in cardiovascular surgery (valve prostheses, artery prostheses) and in orthopedic surgery (arthroplasty, osteosynthesis and arthrotomy) Consideration should be given to official guidance on the appropriate use of antibacterial agents. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The dosage depends on age, weight and renal function of the patient, as well as the severity and nature of the infection. _Adults and adolescents at and over 12 years of age _ Total daily dosage of 1 g to 4 g, administered in three to four divided doses, by i.v. or i.m. injection. Page 3 of 12 In cases of severe infections: Up to 8 g per day administered in four infusions (over 20 to 30 min). No single bolus injection or infusion should exceed 2 g. T Leer el documento completo